Trisalus Life Sciences Inc (TLSI) Stock Price, Quote & News

Company Profile

TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States. It offers Pressure-Enabled Drug Delivery (PEDD) infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; an...

Industry: Medical Devices

Sector: Healthcare

Phone: 888 321 5212

Website: trisaluslifesci.com

Address:

6272 West 91st Avenue, Westminster, United States

AccuRoger Apr. 13 at 12:39 PM

$TLSI This presentation is scheduled for tomorrow at SIR. Quote Dominant fibroid volume reduction ranged from 69% to 89%, which compares favorably with previously reported reductions (42%-58%). Conclusion: The PEDD microcatheter demonstrates a compelling combination of safety, efficacy, and procedural efficiency for symptomatic uterine fibroids. https://www.sirmeeting.org/agenda.asp?BCFO=&pfp=BrowsebyDay&fa=&fb=&fc=&fd=&all=1

0 · Reply

focafoca99 Apr. 10 at 12:19 AM

$TLSI is heading into SIR 2026 with new clinical and preclinical PEDD platform data across multiple tumor types.

0 · Reply

AccuRoger Apr. 8 at 8:59 PM

$TLSI This human trial report was published today. It is small, with powerful results. Enjoy. Quote: Treatment response in the PEDD versus EH groups was complete response 22% vs 0%, partial response 61% vs 64%, stable disease 6% vs 7%, progressive disease 0% vs 29% and overall response 83% vs 64%. P-value for all response data was 0.034, and for ORR was 0.044 (Chi Squared analysis). https://www.jvir.org/article/S1051-0443(26)00115-6/fulltext

0 · Reply

AccuRoger Mar. 18 at 12:41 PM

$TLSI This is a human trial in progress. The abstract is embargoed at the moment. FYI

0 · Reply

DARKP00L Mar. 18 at 12:09 PM

$TLSI 08:07 on Mar. 18 2026 TriSalus Life Sciences Publishes Preclinical Research Evaluating Pressure-Enabled Drug Delivery Of Nelitoliod In Liver Tumor Models In 'Frontiers In Oncology' #tradeideas

0 · Reply

AccuRoger Mar. 15 at 7:07 PM

$TLSI This is a recent article regarding Nelitolimod side effects. It does not change the share price, but it is helpful detail about the low risk related to this therapy across multiple uses. https://pubmed.ncbi.nlm.nih.gov/41819640/

0 · Reply

DonCorleone77 Mar. 6 at 2:09 AM

$TLSI TriSalus Life Sciences sees FY26 revenue $60M-$62M, consensus $60.34M The Company anticipates 2026 revenues in the range of $60 million to $62 million.

0 · Reply

DonCorleone77 Mar. 6 at 2:09 AM

$TLSI TriSalus Life Sciences reports Q4 EPS (21c), consensus (14c) Reports Q4 revenue $13.205M vs $8.261M last year. "During our fourth quarter and throughout 2025, we continued to deliver strong commercial performance, supported by the growing clinical adoption of our TriNav product suite and proprietary PEDD platform across a broad range of solid tumor indications," said Mary Szela, President and CEO of TriSalus. "We are pleased to have exceeded our 2025 revenue guidance of 50%, delivering 53%, reflecting strong commercial execution and sustained progress on our strategic initiatives, including expansion of the TriNav platform across multiple indications beyond the liver."

0 · Reply

StocktwitsEarnings Mar. 5 at 9:11 PM

$TLSI Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$0.21 up 47.50% YoY • Reported revenue of $13.21M up 59.85% YoY • TriSalus anticipates 2026 revenues in the range of $60M to $62M, reaffirming its prior guidance. TriSalus expects to deepen engagement, expand sales, and invest in studies to demonstrate PEDD value.

0 · Reply

StocktwitsEarnings Mar. 5 at 9:11 PM

$TLSI Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$0.21 up 47.50% YoY • Reported revenue of $13.21M up 59.85% YoY • TriSalus Life Sciences reaffirms its 2026 revenue guidance, anticipating revenues to be in the range of $60M to $62M, reflecting confidence in commercial opportunities and long-term vision.

0 · Reply

TriSalus Life Sciences to Present New Data at the 2026 Society of Interventional Radiology Annual Scientific Meeting

Apr 7, 2026, 9:15 AM EDT - 6 days ago

TriSalus Life Sciences Appoints Richard Marshall, M.D., as Chief Medical Officer

Mar 18, 2026, 8:00 AM EDT - 26 days ago

TriSalus Life Sciences Announces Publication Demonstrating Enhanced Delivery and Immune Activation with Nelitolimod Delivered with Pressure-Enabled Drug Delivery in Liver Tumor Models

Mar 5, 2026, 4:01 PM EST - 5 weeks ago

TriSalus Life Sciences Reports Fourth Quarter and Year-End 2025 Results and Reaffirms 2026 Revenue Guidance

Feb 25, 2026, 4:05 PM EST - 6 weeks ago

TriSalus Life Sciences to Host Fourth Quarter 2025 Financial Results Conference Call

Feb 20, 2026, 8:00 AM EST - 7 weeks ago

TriSalus Life Sciences Announces Pricing of $40.0 Million Public Offering

Feb 19, 2026, 4:01 PM EST - 7 weeks ago

TriSalus Life Sciences Proposes Public Offering

Feb 9, 2026, 9:00 AM EST - 2 months ago

TriSalus Life Sciences Appoints Veteran Healthcare Investor Michael Stansky to its Board of Directors

Jan 12, 2026, 7:00 AM EST - 3 months ago

TriSalus Life Sciences Announces Preliminary Fourth Quarter and Full-Year 2025 Results and 2026 Revenue Guidance

Dec 4, 2025, 4:01 PM EST - 4 months ago

TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Symptomatic Thyroid Disease on December 15, 2025

Nov 18, 2025, 8:00 AM EST - 5 months ago

TriSalus Life Sciences Launches TriNav® XP Infusion System to Expand Options for Pressure-Enabled Drug Delivery™

Nov 13, 2025, 4:01 PM EST - 5 months ago

TriSalus Life Sciences Reports Third Quarter 2025 Results and Reaffirms 2025 Revenue Guidance

Nov 11, 2025, 4:05 PM EST - 5 months ago

TriSalus Life Sciences to Participate in Upcoming Investor Conferences

Nov 10, 2025, 8:00 AM EST - 5 months ago

TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Uterine Fibroids on November 12, 2025

Oct 30, 2025, 8:00 AM EDT - 5 months ago

TriSalus Life Sciences to Host Third Quarter 2025 Financial Results Conference Call

Aug 28, 2025, 8:00 AM EDT - 8 months ago

TriSalus Life Sciences to Participate in Upcoming September Investor Conferences

Aug 12, 2025, 4:01 PM EDT - 8 months ago

TriSalus Life Sciences Reports Second Quarter 2025 Results and Reiterates 2025 Guidance

Aug 11, 2025, 8:00 AM EDT - 8 months ago

TriSalus Life Sciences Announces Publication of Safety and Efficacy Results for a Novel Pressure-Enabled Thyroid Embolization Technique

Jul 30, 2025, 4:05 PM EDT - 9 months ago

TriSalus Life Sciences to Participate in the Canaccord Genuity 45th Annual Growth Conference

Jul 29, 2025, 4:05 PM EDT - 9 months ago

TriSalus Life Sciences to Host Second Quarter 2025 Financial Results Conference Call

Jul 24, 2025, 5:58 PM EDT - 9 months ago

TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock

Jun 23, 2025, 5:30 PM EDT - 10 months ago

TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock to Streamline Capital Structure

Jun 4, 2025, 8:00 AM EDT - 11 months ago

TriSalus Life Sciences Announces the Launch of the TriNav FLX Infusion System

May 30, 2025, 7:00 AM EDT - 11 months ago

TriSalus Life Sciences Announces Chief Financial Officer Transition With Appointment of David B. Patience

May 15, 2025, 7:00 AM EDT - 11 months ago

TriSalus Life Sciences Reports First Quarter 2025 Results and Provides Updated 2025 Guidance

May 12, 2025, 4:30 PM EDT - 1 year ago

TriSalus Life Sciences to Host First Quarter 2025 Financial Results Conference Call

Apr 30, 2025, 8:00 AM EDT - 1 year ago

TriSalus Life Sciences Announces $22.0 Million Private Placement Preliminary Q1 2025 Unaudited Financial Results

Mar 27, 2025, 7:30 AM EDT - 1 year ago

TriSalus Life Sciences Reports Q4 and Full Year 2024 Financial Results and Provides Business Update

Mar 26, 2025, 8:00 AM EDT - 1 year ago

TriSalus Life Sciences Announces New CMS HCPCS Code for TriNav® Infusion System Mapping

Mar 6, 2025, 8:00 AM EST - 1 year ago

TriSalus Life Sciences® Announces That Its Researchers Received Two JVIR Top Paper Awards for the Publication of “Intra-arterial Pressure-Enabled Drug Delivery™ Significantly Increases Penetration of Glass Microspheres in a Porcine Liver Tumor Model”

Feb 3, 2025, 4:05 PM EST - 1 year ago

TriSalus Life Sciences Announces Key Appointments to Board of Directors

Feb 3, 2025, 8:00 AM EST - 1 year ago

TriSalus Life Sciences Announces Drawdown of $10 Million Tranche Under Credit Agreement with OrbiMed

Jan 23, 2025, 8:00 AM EST - 1 year ago

TriSalus Life Sciences Announces Preliminary Q4 and Full Year Unaudited 2024 Financial Results and Conference Call

Jan 9, 2025, 8:00 AM EST - 1 year ago

TriSalus Life Sciences® Announces Publication of Pre-Clinical Data Demonstrating Improved Delivery of Embospheres® to Liver Tumors using Pressure-Enabled Drug Delivery™ (PEDD™) via the TriNav® Infusion System

Nov 14, 2024, 8:00 AM EST - 1 year ago

TriSalus Reports Q3 2024 Financial Results and Provides Business Update

Nov 11, 2024, 7:00 AM EST - 1 year ago

TriSalus Life Sciences® Forms Strategic Partnership with Geo-Med, LLC to Expand Access of the TriNav® Infusion System to U.S. Veterans with Liver Cancer

Nov 7, 2024, 7:00 AM EST - 1 year ago

TriSalus Life Sciences Launches TriNav® LV Infusion System and TriGuide™ Guiding Catheters, Expanding Portfolio of PEDD™ Devices for Improved Tumor Treatment

Oct 31, 2024, 8:00 AM EDT - 1 year ago

TriSalus Life Sciences to Host Third Quarter 2024 Financial Results Conference Call

Oct 14, 2024, 4:05 PM EDT - 1 year ago

TriSalus Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit

Sep 26, 2024, 7:00 AM EDT - 1 year ago

TriSalus Life Sciences Announces Appointment of Riad Salem, M.D., to its Scientific Advisory Board

Sep 23, 2024, 7:00 AM EDT - 1 year ago

TriSalus Announces Journal of Vascular and Interventional Radiology Publication of Data that Demonstrate Improved Therapeutic Delivery of Glass Microspheres to Solid Tumors With PEDD™ Method via the TriNav® Infusion System

Aug 15, 2024, 8:00 AM EDT - 1 year ago

TriSalus Reports Q2 2024 Financial Results and Business Update

Aug 1, 2024, 7:00 AM EDT - 1 year ago

TriSalus Life Sciences to Host Second Quarter 2024 Financial Results Conference Call

Jul 1, 2024, 4:00 PM EDT - 1 year ago

TriSalus Life Sciences Announces Completion of Exchange Offer and Consent Solicitation

Jun 26, 2024, 5:45 PM EDT - 1 year ago

TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Warrants

Jun 3, 2024, 7:00 AM EDT - 2 years ago

TriSalus Life Sciences Highlights Clinical Data from Phase 1b PERIO-02 Trial, Studying Delivery of Nelitolimod via Pressure-Enabled Drug Delivery in Patients with Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma at 2024 ASCO Annual Meeting

May 24, 2024, 6:05 AM EDT - 2 years ago

TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Warrants

May 15, 2024, 8:00 AM EDT - 2 years ago

TriSalus Reports Q1 2024 Financial Results and Business Update

May 7, 2024, 7:00 AM EDT - 2 years ago

TriSalus Life Sciences Appoints Liselotte Hyveled to its Board of Directors

May 6, 2024, 4:58 PM EDT - 2 years ago

TriSalus Life Sciences to Host First Quarter 2024 Financial Results Conference Call

AccuRoger Apr. 13 at 12:39 PM

0 · Reply

focafoca99 Apr. 10 at 12:19 AM

$TLSI is heading into SIR 2026 with new clinical and preclinical PEDD platform data across multiple tumor types.

0 · Reply

AccuRoger Apr. 8 at 8:59 PM

0 · Reply

AccuRoger Mar. 18 at 12:41 PM

$TLSI This is a human trial in progress. The abstract is embargoed at the moment. FYI

0 · Reply

DARKP00L Mar. 18 at 12:09 PM

$TLSI 08:07 on Mar. 18 2026 TriSalus Life Sciences Publishes Preclinical Research Evaluating Pressure-Enabled Drug Delivery Of Nelitoliod In Liver Tumor Models In 'Frontiers In Oncology' #tradeideas

0 · Reply

AccuRoger Mar. 15 at 7:07 PM

0 · Reply

DonCorleone77 Mar. 6 at 2:09 AM

$TLSI TriSalus Life Sciences sees FY26 revenue $60M-$62M, consensus $60.34M The Company anticipates 2026 revenues in the range of $60 million to $62 million.

0 · Reply

DonCorleone77 Mar. 6 at 2:09 AM

0 · Reply

StocktwitsEarnings Mar. 5 at 9:11 PM

0 · Reply

StocktwitsEarnings Mar. 5 at 9:11 PM

0 · Reply

topstockalerts Feb. 24 at 2:25 PM

$TLSI heating up…

0 · Reply

PLATINUM_TRADES Feb. 23 at 1:06 PM

$TLSI Let's have another good day! $5.89 Major resistance to break for more 🚨 🚨

0 · Reply

StockScanners Feb. 21 at 6:16 AM

$TLSI keep watch if this holds above 5.50

0 · Reply

StockJelli Feb. 20 at 11:21 PM

Hope everyone is having a Good Friday. Here are the after hours momentum stocks: $RXT $TLSI $RYI $KOS $FNKO

0 · Reply

STACKD0E Feb. 20 at 8:10 PM

$TLSI $20 ✨🙃

0 · Reply

topstockalerts Feb. 20 at 7:58 PM

$TLSI Here comes the breakout as volume expands 📈. Buyers are chasing strength. That usually fuels continuation.

0 · Reply

wjmax Feb. 20 at 6:27 PM

$TLSI has the new drug delivery platform that can deliver drug intratumorally and a TLR9 agonist of which Merck also owns some patents. What else does $TLSI need to combine with in order to have efficacy in treating late stage solid tumor? DCVax-Direct from $NWBO!

1 · Reply

HypnoTrader Feb. 20 at 2:09 PM

$TLSI broke out of the base back in November 25. After significant advance, dropped back to same base in anticipation of an offering. Now that the offering is done, if starts breaking out again, maybe worth building a postition. As some trader once said: market always gives you a second chance.

0 · Reply

BillionerOfKing Feb. 19 at 6:05 PM

$TLSI Current Stock Price: $4.52

0 · Reply

AccuRoger Feb. 4 at 2:25 PM

$TLSI presentation tomorrow is announced: 𝐉𝐨𝐢𝐧 𝐔𝐬 𝐚𝐭 𝐒𝐈𝐎 𝟐𝟎𝟐𝟔 Stop by Booth #303 to explore the TriNav® Infusion System Portfolio. Meet our expert team, explore resources, and see a live demonstration! 𝐉𝐨𝐢𝐧 𝐮𝐬 𝐟𝐨𝐫 𝐎𝐮𝐫 𝐋𝐮𝐧𝐜𝐡 𝐒𝐲𝐦𝐩𝐨𝐬𝐢𝐮𝐦 𝐓𝐢𝐭𝐥𝐞: “Why Pressure Matters: Optimizing Embolic Delivery using TriNav: How Pressure-Enabled Drug Delivery Works and What Real Cases Reveal” 𝐃𝐚𝐭𝐞: Thursday, Feb 5th 𝐓𝐢𝐦𝐞: 1:00 PM – 1:45 PM

1 · Reply

SuperGreenToday Jan. 23 at 6:12 AM

$TLSI

0 · Reply

BillionerOfKing Jan. 22 at 12:53 PM

$TLSI Current Stock Price: $5.52

0 · Reply

Market Cap	258.71M
Revenue (ttm)	45.15M
Net Income (ttm)	-39.23M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-86.89%
Debt to Equity Ratio	-0.98

Volume	181,100
Avg Vol	193,634
Day's Range	N/A - N/A
Shares Out	61.31M
Stochastic %K	76%
Beta	0.54
Analysts	Strong Sell
Price Target	$9.20